NRG Therapeutics has appointed Paul Thompson as its new Chief Development Officer, who brings specialist expertise in neurology to his new role.
Thompson’s experience to date includes translational research, early clinical development, and pharma research and development. He recently served as Chief Scientific Officer at Mission Therapeutics and previously held senior roles at GSK and ONO Pharma UK.
Neil Miller, co-founder and CEO of NRG, said: “Paul’s skills and expertise will enable us to efficiently progress NRG5051 through first-in-human clinical trials, and lay the groundwork for development in other indications, including Parkinson’s.”
Thompson added: “Developing new drugs to treat neurological diseases is very challenging, but I have been very encouraged by the compelling in vivo efficacy data for NRG5051 in rodent models of Parkinson’s and ALS/MND, which has validated the molecules’ novel mechanism of action and demonstrated the therapeutic potential of NRG5051.”
NRG is focused on the discovery of therapeutics which could slow or halt the progression of neurodegenerative disorders such as Parkinson’s and amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND). The company’s s lead asset, NRG5051, has completed investigational new drug-enabling studies and is projected to be used as treatment for the first time in 2026.